• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019.

作者信息

Ji Fanpu, Li Liya, Li Zongfang, Jin Yan, Liu Wenjia

机构信息

Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.

State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, People's Republic of China.

出版信息

Stem Cells Transl Med. 2020 Jul;9(7):813-814. doi: 10.1002/sctm.20-0083. Epub 2020 Apr 22.

DOI:10.1002/sctm.20-0083
PMID:32320535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7264790/
Abstract
摘要

相似文献

1
Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019.间充质干细胞作为2019冠状病毒病重症患者的一种潜在治疗方法。
Stem Cells Transl Med. 2020 Jul;9(7):813-814. doi: 10.1002/sctm.20-0083. Epub 2020 Apr 22.
2
Reply to Wengenmayer : Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19-related Acute Respiratory Distress Syndrome: Worth the Effort!回复温根迈尔：体外膜肺氧合用于治疗 COVID-19 相关急性呼吸窘迫综合征的重症患者：值得一试！
Am J Respir Crit Care Med. 2020 Nov 15;202(10):1479-1480. doi: 10.1164/rccm.202007-2670LE.
3
Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment.间充质干细胞来源的细胞外囊泡用于治疗新冠病毒病
Drug Discov Today. 2020 Jul;25(7):1124-1125. doi: 10.1016/j.drudis.2020.04.022. Epub 2020 May 6.
4
Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS).体外膜肺氧合（ECMO）在 2019 冠状病毒病（COVID-19）肺炎和急性呼吸窘迫综合征（ARDS）危重症患者中的应用。
Med Sci Monit. 2020 Aug 6;26:e925364. doi: 10.12659/MSM.925364.
5
Extracorporeal membrane oxygenation for acute respiratory distress syndrome in patients with coronavirus disease 2019: what do we know so far?2019冠状病毒病患者急性呼吸窘迫综合征的体外膜肺氧合：我们目前了解多少？
Perfusion. 2020 Sep;35(6):558-561. doi: 10.1177/0267659120934279. Epub 2020 Jun 24.
6
Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome?2019冠状病毒病是否反驳了急性呼吸窘迫综合征中的肥胖悖论？
Obesity (Silver Spring). 2020 Jun;28(6):1007. doi: 10.1002/oby.22835.
7
Fibrin-derived peptide Bβ15-42 (FX06) as salvage treatment in critically ill patients with COVID-19-associated acute respiratory distress syndrome.纤维蛋白衍生肽Bβ15 - 42（FX06）作为新型冠状病毒肺炎相关急性呼吸窘迫综合征重症患者的挽救治疗手段
Crit Care. 2020 Sep 24;24(1):574. doi: 10.1186/s13054-020-03293-8.
8
Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.2019冠状病毒病阴影下的急性呼吸窘迫综合征与类固醇
Pol Arch Intern Med. 2020 Apr 30;130(4):266-267. doi: 10.20452/pamw.15325.
9
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.细胞疗法治疗呼吸道病毒感染的现状：在 COVID-19 中的适用性。
Eur Respir J. 2020 Jun 4;55(6). doi: 10.1183/13993003.00858-2020. Print 2020 Jun.
10
Ethics and extracorporeal membrane oxygenation during coronavirus disease 2019 outbreak.2019冠状病毒病疫情期间的伦理与体外膜肺氧合
Perfusion. 2020 Sep;35(6):562-564. doi: 10.1177/0267659120937545. Epub 2020 Jun 25.

引用本文的文献

1
Immune-Cell-Based Therapy for COVID-19: Current Status.基于免疫细胞的 COVID-19 治疗：现状。
Viruses. 2023 Oct 25;15(11):2148. doi: 10.3390/v15112148.
2
Extracellular Vesicles as a Translational Approach for the Treatment of COVID-19 Disease: An Updated Overview.细胞外囊泡作为治疗 COVID-19 疾病的转化方法：最新综述。
Viruses. 2023 Sep 22;15(10):1976. doi: 10.3390/v15101976.
3
Immune cells-derived exosomes: A promising strategy for COVID-19 treatment.免疫细胞衍生的外泌体：一种有前景的 COVID-19 治疗策略。

本文引用的文献

1
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
2
Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome.间充质干细胞衍生的细胞外囊泡治疗急性呼吸窘迫综合征。
Stem Cells Transl Med. 2020 Jan;9(1):28-38. doi: 10.1002/sctm.19-0205. Epub 2019 Oct 24.
3
Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome.
Clin Transl Discov. 2022 Oct 10;2(4):e138. doi: 10.1002/ctd2.138. eCollection 2022 Dec.
4
Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice.间充质干细胞及间充质干细胞衍生的细胞外囊泡在传染病中的应用：从基础研究到临床实践
Bioengineering (Basel). 2022 Nov 8;9(11):662. doi: 10.3390/bioengineering9110662.
5
Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy.组织修复策略：从 COVID-19 中学到的关于间充质干细胞治疗的应用。
Pharmacol Res. 2022 Aug;182:106334. doi: 10.1016/j.phrs.2022.106334. Epub 2022 Jun 30.
6
Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.聚焦间充质干细胞在病毒感染中的治疗效率，重点关注 COVID-19。
Stem Cell Res Ther. 2022 Jun 17;13(1):257. doi: 10.1186/s13287-022-02944-7.
7
Stem cell-derived biofactors fight against coronavirus infection.干细胞衍生的生物因子对抗冠状病毒感染。
World J Stem Cells. 2021 Dec 26;13(12):1813-1825. doi: 10.4252/wjsc.v13.i12.1813.
8
Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application.间质干细胞治疗博来霉素诱导的肺纤维化的疗效：系统评价及临床应用意义。
Stem Cell Res Ther. 2021 Aug 23;12(1):470. doi: 10.1186/s13287-021-02551-y.
9
Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19.纳米生物材料在现代世界的应用：组织工程与新冠疫情
Front Bioeng Biotechnol. 2021 May 14;9:597958. doi: 10.3389/fbioe.2021.597958. eCollection 2021.
10
Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19).生物材料在2019冠状病毒病（COVID-19）诊断、预防、治疗及研究中的作用
Emergent Mater. 2021;4(1):35-55. doi: 10.1007/s42247-021-00165-x. Epub 2021 Mar 16.
在急性呼吸窘迫综合征的治疗中，用自身血清重编程的间充质干细胞表现出增强的治疗特性。
Stem Cells Transl Med. 2019 Oct;8(10):1092-1106. doi: 10.1002/sctm.18-0236. Epub 2019 Jun 20.
4
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.同种异体间充质基质细胞治疗中重度急性呼吸窘迫综合征（START 研究）：一项随机 2a 期安全性试验。
Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.
5
Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury.人脐带间充质干细胞减轻甲型 H5N1 流感病毒相关急性肺损伤的治疗意义。
J Infect Dis. 2019 Jan 7;219(2):186-196. doi: 10.1093/infdis/jiy478.
6
Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer.间充质基质细胞通过细胞外囊泡线粒体转移在临床相关肺损伤模型中调节巨噬细胞。
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1275-1286. doi: 10.1164/rccm.201701-0170OC.
7
Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes.简明综述：基于间充质基质细胞的方法治疗急性呼吸窘迫和脓毒症综合征。
Stem Cells Transl Med. 2017 Apr;6(4):1141-1151. doi: 10.1002/sctm.16-0415. Epub 2017 Jan 9.
8
In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.间充质基质细胞对两名重症急性呼吸窘迫综合征患者的体内影响
Stem Cells Transl Med. 2015 Oct;4(10):1199-213. doi: 10.5966/sctm.2015-0021. Epub 2015 Aug 18.
9
Mesenchymal stem cells: a new strategy for immunosuppression?间充质干细胞：一种免疫抑制的新策略？
Trends Immunol. 2007 May;28(5):219-26. doi: 10.1016/j.it.2007.03.001. Epub 2007 Apr 2.
10
Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge.SARS康复出院患者血清SARS冠状病毒IgG、肺功能及影像学的动态变化
Respir Res. 2005 Jan 8;6(1):5. doi: 10.1186/1465-9921-6-5.